Breakdown | ||||
Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|
Income Statement | Total Revenue | |||
191.59M | 5.45M | 6.15M | 0.00 | 35.00M | Gross Profit |
179.04M | 5.03M | 4.25M | -490.00K | 34.65M | EBIT |
-278.13M | -343.01M | -280.67M | -173.47M | -46.32M | EBITDA |
-278.13M | -341.35M | -280.67M | -172.98M | -45.98M | Net Income Common Stockholders |
-258.13M | -325.10M | -274.16M | -173.21M | -44.24M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
307.99M | 479.20M | 597.01M | 373.50M | 508.48M | Total Assets |
587.28M | 725.79M | 630.24M | 452.49M | 576.19M | Total Debt |
7.91M | 7.06M | 5.25M | 1.29M | 2.73M | Net Debt |
-61.84M | -169.00M | -62.24M | -102.67M | -144.35M | Total Liabilities |
106.17M | 99.57M | 72.05M | 30.10M | 19.13M | Stockholders Equity |
481.10M | 626.22M | -569.93M | 422.40M | 557.06M |
Cash Flow | Free Cash Flow | |||
-180.05M | -230.18M | -171.76M | -129.89M | -32.83M | Operating Cash Flow |
-175.60M | -222.79M | -161.56M | -127.88M | -32.19M | Investing Cash Flow |
64.55M | 34.75M | -215.60M | 83.59M | -418.83M | Financing Cash Flow |
4.76M | 296.64M | 340.70M | 1.16M | 270.49M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
60 Neutral | $3.90B | ― | -27.92% | ― | ― | -31.37% | |
54 Neutral | $3.49B | ― | -51.57% | ― | 730.42% | 31.63% | |
53 Neutral | $5.14B | 3.03 | -43.89% | 2.83% | 16.75% | -0.06% | |
52 Neutral | $3.95B | ― | -418.97% | ― | 48.88% | 39.30% | |
50 Neutral | $3.24B | ― | -19.71% | ― | -86.13% | -67.29% | |
48 Neutral | $2.83B | 60.02 | 8.99% | ― | -34.02% | -65.83% | |
43 Neutral | $3.37B | ― | -386.33% | ― | 33.46% | 26.72% |
On May 14, 2025, SpringWorks Therapeutics held its annual stockholders meeting, during which key proposals were voted on. Stockholders elected Class III directors, ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for 2025, and approved executive compensation on a non-binding advisory basis. These decisions are expected to influence the company’s governance and financial oversight, potentially impacting its strategic direction and stakeholder confidence.
The most recent analyst rating on (SWTX) stock is a Hold with a $47.00 price target. To see the full list of analyst forecasts on Springworks Therapeutics stock, see the SWTX Stock Forecast page.
On April 27, 2025, SpringWorks Therapeutics entered into a merger agreement with Merck KGaA, Darmstadt, Germany, where SpringWorks will become a wholly owned subsidiary of Merck. The acquisition, valued at approximately $3.9 billion, aims to strengthen Merck’s presence in the U.S. healthcare market and expand the reach of SpringWorks’ therapies for rare tumors. The merger is expected to enhance Merck’s revenue and earnings growth, while providing SpringWorks with the opportunity to leverage Merck’s global resources and expand its market reach.